Jazz Pharmaceuticals Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Johnson & Johnson's revenue, earnings per share (EPS) and valuation.

Johnson & Johnson has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Jazz Pharmaceuticals and Johnson & Johnson, as provided by MarketBeat.

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Johnson & Johnson has a consensus target price of $182.6154, indicating a potential upside of 12.56%. Given Johnson & Johnson's higher probable upside, analysts plainly believe Johnson & Johnson is more favorable than Jazz Pharmaceuticals.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Jazz Pharmaceuticals and Johnson & Johnson's net margins, return on equity and return on assets.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, profitability, valuation, dividends and risk.

Earnings and Valuation

This table compares Jazz Pharmaceuticals and Pfizer's revenue, earnings per share (EPS) and valuation.

Pfizer has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Jazz Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, meaning that its share price is 30% less volatile than the S&P 500.

Institutional and Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.4% of Pfizer shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of Pfizer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Jazz Pharmaceuticals and Pfizer, as provided by MarketBeat.

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Pfizer has a consensus target price of $38.5714, indicating a potential upside of 0.00%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Jazz Pharmaceuticals is more favorable than Pfizer.

Profitability

This table compares Jazz Pharmaceuticals and Pfizer's net margins, return on equity and return on assets.

Summary

Jazz Pharmaceuticals beats Pfizer on 10 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Merck & Co., Inc. (NYSE:MRK) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Merck & Co., Inc.'s revenue, earnings per share (EPS) and valuation.

Merck & Co., Inc. has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.9% of Merck & Co., Inc. shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Merck & Co., Inc., as provided by MarketBeat.com.

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Merck & Co., Inc. has a consensus target price of $96.2727, indicating a potential upside of 24.27%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts clearly believe Merck & Co., Inc. is more favorable than Jazz Pharmaceuticals.

Profitability

This table compares Jazz Pharmaceuticals and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and AbbVie (NYSE:ABBV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and AbbVie's revenue, earnings per share (EPS) and valuation.

AbbVie has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 67.5% of AbbVie shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and AbbVie, as provided by MarketBeat.com.

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. AbbVie has a consensus target price of $115.75, indicating a potential upside of 7.27%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than AbbVie.

Profitability

This table compares Jazz Pharmaceuticals and AbbVie's net margins, return on equity and return on assets.

Summary

Jazz Pharmaceuticals beats AbbVie on 8 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Eli Lilly and's revenue, earnings per share (EPS) and valuation.

Eli Lilly and has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, meaning that its stock price is 63% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Eli Lilly and, as provided by MarketBeat.com.

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Eli Lilly and has a consensus target price of $196.40, indicating a potential upside of 3.78%. Given Jazz Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Jazz Pharmaceuticals is more favorable than Eli Lilly and.

Profitability

This table compares Jazz Pharmaceuticals and Eli Lilly and's net margins, return on equity and return on assets.

Summary

Jazz Pharmaceuticals beats Eli Lilly and on 8 of the 14 factors compared between the two stocks.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Bristol-Myers Squibb (NYSE:BMY) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, risk, dividends and valuation.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Bristol-Myers Squibb's revenue, earnings per share (EPS) and valuation.

Bristol-Myers Squibb has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Jazz Pharmaceuticals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.67, meaning that its stock price is 33% less volatile than the S&P 500.

Institutional & Insider Ownership

95.7% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.4% of Bristol-Myers Squibb shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Jazz Pharmaceuticals and Bristol-Myers Squibb, as provided by MarketBeat.com.

Jazz Pharmaceuticals currently has a consensus target price of $186.7778, indicating a potential upside of 10.58%. Bristol-Myers Squibb has a consensus target price of $74.60, indicating a potential upside of 13.96%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts clearly believe Bristol-Myers Squibb is more favorable than Jazz Pharmaceuticals.

Profitability

This table compares Jazz Pharmaceuticals and Bristol-Myers Squibb's net margins, return on equity and return on assets.

Summary

Jazz Pharmaceuticals beats Bristol-Myers Squibb on 8 of the 15 factors compared between the two stocks.